Innoveren Scientific (IVRN) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Cover [Abstract]
Entity Registrant Name	H-CYTE, INC.
Entity Central Index Key	0001591165
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		144,434,230
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current Assets
Cash	$ 332,310	$ 1,640,645
Accounts receivable	40,500
Other receivables	1,137	22,123
Prepaid expenses	209,461	94,434
Total Current Assets	583,408	1,757,202
Right-of-use asset	204,546	278,552
Property and equipment, net	129,126	139,175
Other assets	29,239	29,239
Total assets	946,319	2,204,168
Current Liabilities
Accounts payable	1,149,597	1,006,968
Accrued liabilities	236,777	276,415
Other current liabilities	324,601	154,812
Notes payable, current portion	67,444	67,444
PPP Loan, current portion	746,845	606,811
Interest payable	10,838	6,898
Deferred revenue	581,259	634,149
Lease liability, current portion	87,939	139,189
Total Current Liabilities	3,205,300	2,892,686
Long-term Liabilities
Lease liability, net of current portion	134,295	157,050
PPP Loan, net of current portion	62,237	202,271
Total Long-term Liabilities	196,532	359,321
Total Liabilities	3,401,832	3,252,007
Stockholders' Equity (Deficit)
Preferred Stock - $.001 par value: 1,000,000,000 shares authorized; Series A Preferred Stock - $.001 par value: 800,000,000 shares authorized, 528,429,575 and 538,109,409 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	528,429	538,109
Common stock - $.001 par value: 1,600,000,000 shares authorized, 136,839,298 and 127,159,464 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	136,839	127,159
Additional paid-in capital	42,515,999	42,515,999
Accumulated deficit	(45,266,648)	(43,858,974)
Non-controlling interest	(370,132)	(370,132)
Total Stockholders' Deficit	(2,455,513)	(1,047,839)
Total Liabilities and Stockholders' Deficit	$ 946,319	$ 2,204,168

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,600,000,000	1,600,000,000
Common stock, shares issued	136,839,298	127,159,464
Common stock, shares outstanding	136,839,298	127,159,464
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	800,000,000	800,000,000
Preferred stock, shares issued	528,429,575	538,109,409
Preferred stock, shares outstanding	528,429,575	538,109,409

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenues	$ 376,168	$ 1,016,776
Cost of Sales	(198,649)	(376,816)
Gross Profit	177,519	639,960
Operating Expenses
Salaries and related costs	661,775	1,224,353
Other general and administrative	830,113	1,230,135
Research and development		750,000
Advertising	77,228	144,618
Depreciation and amortization	11,571	22,108
Total Operating Expenses	1,580,687	3,371,214
Operating Loss	(1,403,168)	(2,731,254)
Other Income (Expense)
Other Income (Expense)	1,278	2,538
Interest expense	(5,784)	(56,149)
Change in fair value of redemption put liability		193,659
Change in fair value of derivative liability - warrants		174,978
Total Other Income (Expense)	(4,506)	315,026
Net Loss	(1,407,674)	(2,416,228)
Accrued dividends on outstanding Series B Convertible Preferred Stock		18,300
Deemed dividend on Series D Convertible Preferred Stock		158,147
Net loss attributable to common stockholders	$ (1,407,674)	$ (2,592,675)
Loss per share - Basic and Diluted	$ (0.01)	$ (0.03)
Weighted average outstanding shares - basic and diluted	128,283,919	99,839,617

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Series A Stock [Member]	Preferred Series B Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Beginning Balance at Dec. 31, 2019		$ 6	$ 99,769	$ 28,172,146	$ (37,362,531)	$ (370,132)	$ (9,460,742)
Beginning Balance, Shares at Dec. 31, 2019		6,100	99,768,704
Issuance of common stock in exchange for consulting fees incurred			$ 109	34,891			35,000
Issuance of common stock in exchange for consulting fees incurred, shares			109,375
Issuance of warrants pursuant to short-term notes, related party				17,636			17,636
Deemed dividend on Series D Convertible Preferred Stock				(120,940)	(37,207)		(158,147)
Issuance of warrants pursuant to private placement of Series D Convertible Preferred Stock				31,902			31,902
Stock based compensation				643			643
Accrued dividends on Series B Convertible Preferred Stock				(18,300)			(18,300)
Net loss					(2,416,228)		(2,416,228)
Ending Balance at Mar. 31, 2020		$ 6	$ 99,878	28,117,978	(39,815,966)	(370,132)	(11,968,236)
Ending Balance, shares at Mar. 31, 2020		6,100	99,878,079
Beginning Balance at Dec. 31, 2020	$ 538,109		$ 127,159	42,515,999	(43,858,974)	(370,132)	(1,047,839)
Beginning Balance, Shares at Dec. 31, 2020	538,109,409		127,159,464
Conversion of Series A Preferred Stock to Common Stock	$ (9,680)		$ 9,680
Conversion of Series A Preferred Stock to Common Stock, shares	(9,679,834)		9,679,834
Net loss					(1,407,674)		(1,407,674)
Ending Balance at Mar. 31, 2021	$ 528,429		$ 136,839	$ 42,515,999	$ (45,266,648)	$ (370,132)	$ (2,455,513)
Ending Balance, shares at Mar. 31, 2021	528,429,575		136,839,298

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows from Operating Activities
Net loss	$ (1,407,674)	$ (2,416,228)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,571	22,108
Amortization of debt discount		912
Issuance of warrants pursuant to short-term notes, related party		17,636
Stock based compensation		643
Common stock issued for consulting services		35,000
Change in fair value of derivative liability - warrants and redemption put liability		(368,637)
Bad debt expense		3,000
Changes in operating assets and liabilities:
Accounts receivable	(40,500)	8,334
Other receivables	20,986	6,972
Prepaid expenses and other assets	(115,026)	594,251
Interest payable	3,940	39,363
Accounts Payable	142,629	204,843
Accrued liabilities	(39,638)	211,221
Other current liabilities	169,789	25,948
Deferred revenue	(52,890)	(276,125)
Net Cash Used in Operating Activities	(1,306,813)	(1,890,759)
Cash Flows from Investing Activities
Purchase of property and equipment	(1,522)
Net Cash Used in Investing Activities	(1,522)
Cash Flows from Financing Activities
Proceeds from short-term related party notes		500,000
Payments on debt obligations		(10,937)
Proceeds from issuance of Series D Convertible Preferred Stock		100,000
Net Cash Provided by Financing Activities		589,063
Net Decrease in Cash	(1,308,335)	(1,301,696)
Cash - Beginning of period	1,640,645	1,424,096
Cash - End of period	332,310	122,400
Supplementary Cash Flow Information
Cash paid for interest	1,844	15,874
Non-cash investing and financing activities
Deemed dividend on Series D Convertible Preferred Stock		158,147
Issuance of Warrants in connection with Series D Convertible Preferred Stock		31,902
Dividends accrued on Series B Convertible Preferred Stock		$ 18,300

Description of the Company

Description of the Company	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Description of the Company	Note 1 - Description of the Company H-CYTE, Inc is a hybrid-biopharmaceutical company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders. During the last two years, the Company has evolved into two separate verticals under its Healthcare Medical Biosciences Division with its entrance into the biologics development space (“Biologics Vertical”). This new vertical is complementary to the Company’s current Lung Health Institute (LHI) autologous infusion therapy business (“Infusion Vertical”) and is focused on underserved disease states. The consolidated results for H-CYTE include the following wholly-owned subsidiaries: H-CYTE Management, LLC (formerly Blue Zone Health Management, LLC), MedoveX Corp, Cognitive Health Institute, LLC, and Lung Institute Tampa, LLC (formerly Blue Zone Lung Tampa, LLC) and the results include Lung Institute Dallas, PLLC (“LI Dallas”), Lung Institute Nashville, PLLC (“LI Nashville”), Lung Institute Pittsburgh, PLLC (“LI Pittsburgh”), and Lung Institute Scottsdale, LLC (“LI Scottsdale”), as Variable Interest Entities (“VIEs”). Additionally, H-CYTE Management, LLC is the operator and manager of the various Lung Health Institute (LHI) clinics: LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC, Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC”) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company (for further discussion, see Notes 8 and 9-”Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). The Company has two divisions: the Healthcare Medical Biosciences Division (which includes the “Infusion Vertical” and the “Biologics Vertical”) and the DenerveX medical device division (“DenerveX”). The Company has decided to focus its available resources on the Healthcare Medical Biosciences Division as it represents a significantly greater opportunity than the DenerveX division. Following this decision, on April 2, 2021, the Company entered into a series of agreements with Medovex, LLC to pursue a joint venture regarding the continued development and commercialization of the DenerveX Device for business outside the U.S. (see Note 14). Healthcare Medical Biosciences Division (“Biosciences Division”) Autologous Infusion Therapy (“Infusion Vertical”) The Company’s Biosciences Division includes the Infusion Vertical that develops and implements innovative treatment options in autologous cellular therapy (PRP-PBMC) to treat chronic lung disorders. Committed to an individualized patient-centric approach, this division provides oversight and management of the highest quality to the LHI clinics, while producing positive medical outcomes following the strictest CDC guidelines. Biotech Development Division (“Biologics Vertical”) On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. With these agreements, Rion will serve as the product supplier and contracted preclinical development arm of the biologic. H-CYTE will control the commercial development and the clinical trial investigation. After conducting the clinical efficacy trials of this biologic, H-CYTE intends to pursue submission of a Biologics License Application (“BLA”) for review by the FDA for treatment of COPD. DenerveX Medical Device Division (DenerveX) In the first quarter of 2020, the Company made the decision to stop any further efforts to source alternative manufacturing and distributor options for the DenerveX product. The Company has decided to focus its available resources on the Biosciences Division as this division presents a significantly greater opportunity. Following this decision, on April 2, 2021, the Company entered into a series of agreements with Medovex, LLC to pursue a joint venture regarding the continued development and commercialization of the DenerveX Device for business outside of the U.S. (see Note 14).

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 2 – Basis of presentation The accompanying interim consolidated financial statements have been prepared based upon U.S. Securities and Exchange Commission rules that permit reduced disclosure for interim periods. Therefore, they do not include all information and footnote disclosures necessary for a complete presentation of the Company’s financial position, results of operations and cash flows, in conformity with generally accepted accounting principles. The Company filed audited consolidated financial statements as of and for the fiscal years ended December 31, 2020 and 2019, which included all information and notes necessary for such complete presentation in conjunction with its 2020 Annual Report on Form 10-K. The results of operations for the interim period ended March 31, 2021 are not necessarily indicative of the results to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020, which are contained in the Company’s 2020 Annual Report on Form 10-K. For further discussion refer to Note 2–”Basis Of Presentation And Summary of Significant Accounting Policies” to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations–Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Liquidity, Going Concern and Ma

Liquidity, Going Concern and Management's Plans	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Going Concern and Management's Plans	Note 3 - Liquidity, Going Concern and Management’s Plans The Company incurred net losses of approximately $1,408,000 and $2,416,000 for the three months ended March 31, 2021 and 2020, respectively. The Company has historically incurred losses from operations and expects to continue to generate negative cash flows as it implements its plan around the Biosciences Division. The consolidated financial statements are prepared using accounting principles generally accepted in the United States (“U.S. GAAP”) as applicable to a going concern. COVID-19 has adversely affected the Company’s financial condition and results of operations. The impact of the outbreak of COVID-19 on the economy in the U.S. and the rest of the world is expected to continue to be significant. The extent to which the COVID-19 outbreak will continue to impact the economy is highly uncertain and cannot be predicted. Accordingly, the Company cannot predict the extent to which its financial condition and results of operations will be affected. The Company has updated its business model to decrease corporate overhead and marketing activities to significantly reduce expenses. The Company believes that as COVID-19 begins to dissipate due to vaccinations being administered nationwide, patients will again feel comfortable traveling to one of the LHI clinics for its treatment. The Company’s Biologics Vertical has commenced preclinical work in support of filing an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration (“FDA”). The Company is anticipating an initial submission during the second half of 2021. Note Purchase Agreements On April 17, 2020, and in subsequent April closings, the Company entered into a Secured Convertible Note and Warrant Purchase Agreement (the “April SPA”) with thirty three investors (the “Purchasers”) pursuant to which the Company received an aggregate of $2,842,695 in gross proceeds through the sale to the Purchasers of Secured Convertible Promissory Notes (the “April Secured Notes”) and warrants (the “April Warrants”) to purchase shares of common stock of the Company (the “April Offering”). The proceeds of the April Offering will be used for working capital and general corporate purposes. The April Offering resulted in the issuance of April Secured Notes to Purchasers in an aggregate principal amount of $3,842,695. This sum included the issuance by the Company to FWHC Bridge, LLC (the “Investor) of an April Secured Note in the amount of $1,000,000 to amend and supersede the A&R Note (see below “Short-term Notes, Related Parties”) previously issued by the Company to the Investor on April 9, 2020. The Investor is an affiliate of FWHC Holdings, LLC, a pre-existing shareholder of the Company, which served as lead investor in the Company’s recent Series D Convertible Preferred Stock Offering. Additionally, in connection with the April Offering, the Company entered into an amendment with the Investor with respect to the outstanding 12% Senior Secured Convertible Note due September 30, 2020, which was originally issued in 2018 and assumed in the Merger and purchased by the Investor from its original holder, George Hawes, on March 27, 2020 (the “Hawes Note”). The Hawes Notes had a principal amount of $424,615 as of March 31, 2020. The amendment to the Hawes Note eliminated the requirement that the Company make monthly payments of accrued interest. As part of the April Offering, the holders of certain existing warrants issued by the Company, which contained anti-dilution price protection, entered into agreements terminating all anti-dilution price protection in their warrants. The Company implemented a one-time reduction of the exercise price of such warrants to be equal to the price per share of preferred stock totaling $0.014 per share for the Qualified Financing. The Qualified Financing closed on September 11, 2020 triggering the reset of certain existing warrants to $0.014 per share and the conversion of the April Secured Notes plus accrued interest into 287,984,337 Preferred A shares. The Company also converted the Hawes notes plus accrued interest into 35,860,079 shares of Preferred A shares upon the closing of the Qualified Financing (for further discussion, see Note 9-”Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). Short-term Notes, Related Parties On March 27, 2020, the Company issued a demand note (the “Note”) in the principal amount of $500,000 to FWHC Bridge, LLC (the “Investor”) in exchange for a loan made by the Investor in such amount to cover the Company’s working capital needs. Subsequently, on April 9, 2020, in exchange for an additional loan of $500,000 made by the Investor to the Company, to further cover the Company’s working capital needs, the Company amended and restated the demand note to reflect a new principal amount of $1,000,000 (the “A&R Note”). The A&R Note bore simple interest at a rate of 12% per annum. The Investor is an affiliate of FWHC Holdings, LLC which is a pre-exiting shareholder of the Company. As discussed further above in “Note Purchase Agreements”, this A&R Note was further amended and superseded by an April Secured Note in the amount of $1,000,000 issued by the Company to the Investor. As explained above, the A&R Note was converted to Series A Preferred stock on September 11, 2020, the closing date of the Qualified Financing. The short-term notes with related parties were issued by the Company during 2019, and as of March 31, 2020 consisted of four loans totaling $1,635,000, made to the Company by Horne Management, LLC, controlled by the former Chief Executive Officer, William E. Horne, for working capital purposes. The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020. Some of these loans provided for the issuance of warrants at 114% warrant coverage if the loan was not repaid within two months. None of these loans were repaid and 840,000 warrants were issued at an exercise price of $0.75 per share. On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020. This warrant has an exercise price equal to the price per share at which securities were offered to investors for purchase at the Qualified Financing totaling $0.014 and is exercisable beginning on the day immediately following the earlier to occur of (x) the closing of the Qualified Financing and (y) November 1, 2020. The Qualified Financing closed on September 11, 2020 (for further discussion, see Note 9-”Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). On April 1, 2021, the Company, entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $2,575,000. The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8%. The Notes are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the April 2021 Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $1,500,000 of the total amount to the Company. FWHC is an affiliated entity of FWHC, LLC, which is a principal stockholder of the Company. An additional affiliate of FWHC, LLC advanced an additional $25,000 (see Note 14). Since the number of shares the holder will receive upon a Qualified Financing is not known until the financing occurs, a contingent beneficial conversion feature will be calculated and recorded when the financing is completed. The Company had cash on hand of approximately $332,000 as of March 31, 2021 and approximately $2,133,000 as of May 13, 2021. The Company’s cash is insufficient to fund its operations over the next year and the Company is currently working to obtain additional debt or equity financing to help support the Biosciences Division’s business model. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. If the Company is unable to fund its operations from existing cash on hand, operating cash flows, additional borrowings, or raising equity capital, the Company may be forced to discontinue operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Right-of-use Asset and Lease Li

Right-of-use Asset and Lease Liability	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Right-of-use Asset and Lease Liability	Note 4 – Right-of-use Asset And Lease Liability The components of lease expense, which are included in other general and administrative expense, for the three months ended March 31, 2021 and 2020, respectively, are as follows: Three months Ended March 31, 2021 2020 Operating lease expense $ 108,593 $ 150,564 Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2021 and 2020, respectively, are as follows: Three months Ended March 31, 2021 2020 Operating cash flows from operating leases $ 108,593 $ 150,564 Supplemental balance sheet and other information related to operating leases are as follows: March 31, 2021 December 31, 2020 Operating leases right-of-use assets $ 204,546 $ 278,552 Lease liability, current portion 87,939 139,189 Lease liability, net of current portion 134,295 157,050 Total operating lease liabilities $ 222,234 $ 296,239 Weighted average remaining lease term 2.42 years 2.32 years Weighted average discount rate 11.57 % 10.31 % Future maturities of operating lease liabilities as of March 31, 2021 are as follows: Operating leases Remainder of 2021 $ 75,712 2022 102,891 2023 69,333 Total lease payments 247,936 Less: Interest (25,702 ) Total lease liability $ 222,234 The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a short-term lease for its Tampa location beginning April 1, 2021 totaling $71,775. The Dallas, TX lease expired on July 31, 2020 and the Pittsburgh, PA lease expired on October 31, 2020, neither of which were renewed as these clinic locations were permanently closed. The Company has decided that its corporate staff will continue working remotely but the Company will have a small corporate meeting room in the Tampa LHI clinic.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 - Property And Equipment Property and equipment, net, consists of the following: Useful Life March 31, 2021 December 31, 2020 Furniture and fixtures 5-7 years $ 231,222 $ 231,222 Computers and software 3-7 years 247,844 246,323 Leasehold improvements 15 years 155,583 155,583 634,649 633,128 Less: accumulated depreciation (505,523 ) (493,953 ) Total $ 129,126 $ 139,175 Depreciation expense was approximately $12,000 and $22,000 for the three months ended March 31, 2021 and 2020, respectively. The Company uses the straight-line depreciation method to calculate depreciation expense.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions Board Members and Officers and Related Expenses Effective February 1, 2019, the Company entered into an oral consulting agreement with Mr. Raymond Monteleone, Board Member and Chairman of the Audit Committee in which Mr. Monteleone received $10,000 per month for advisory services and $5,000 per quarter as Audit Committee Chair in addition to regular quarterly board meeting fees. Effective March 25, 2020, the Company reduced the advisory services to $5,000 per month and the fees per quarter as the Audit Committee Chair to $2,500 per quarter. On January 12, 2021, Mr. Monteleone was appointed as Chairman of the Board and Compensation Committee Chair. There are understandings between the Company and Mr. Monteleone for him to receive $4,167 per month to serve on the Board of Directors and an additional $5,000 per quarter to serve as Chairman of the Board, Audit Committee Chair, and Compensation Committee Chair. The Company expensed approximately $17,500 and $30,000 in compensation to Mr. Monteleone for the three months ended March 31, 2021 and 2020 respectively. Effective October 1, 2020, the Company entered into an oral agreement with Mr. Michael Yurkowsky in which Mr. Yurkowsky will receive $4,167 per month to serve on the Board of Directors. The Company expensed approximately $12,500, and $0 in compensation to Mr. Yurkowsky for the three months ended March 31, 2021 and 2020 respectively. On January 12, 2021, Mr. William Horne stepped down as Chairman of the Board. Mr. Horne will remain a member of the Board. Effective March 1, 2021, the Company entered into an oral agreement with Mr. Horne in which Mr. Horne will receive $4,167 per month to serve on the Board of Directors. The Company expensed approximately $4,000, and $0 in Board fee compensation to Mr. Horne for the three months ended March 31, 2021 and 2020, respectively. Debt and Other Obligations The short-term notes, related parties are detailed in Note 3-”Liquidity, Going Concern and Management’s Plans” in this Form 10-Q. Change in Control On September 11, 2020, with the closing of the Rights Offering, FWHC, LLC, FWHC Bridge, LLC, and FWHC Bridge Friends, LLC (collectively known as “FWHC) gained control of the Company by subsequently owning approximately 61% of the fully diluted shares of the Company. On July 28, 2020, the Company issued an aggregate of 15,518,111 shares of its common stock to FWHC upon the conversion of its issued Series D Convertible Preferred Stock. The Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations for the Series D Convertible Preferred Stock. On September 11, 2020, with the closing of the Rights Offering, FWHC was issued 123,031,819 shares of Preferred A Stock for conversion of the outstanding promissory notes from April 2020, 75,162,429 shares of Preferred A Stock for conversion of the April Secured Note, 35,860,079 shares of Preferred A Stock for conversion of the Hawes Notes, and 117,362,143 shares of Preferred A Stock issued upon the closing of the Rights Offering. FWHC was also issued 273,356,676 10-year warrants at $0.014 upon the closing of the Rights Offering.

Equity Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Equity Transactions	Note 7 - Equity Transactions Common Stock Issuance In February 2020, the Company issued LilyCon Investments $35,000 in shares of the Company’s common stock at a weighted average share price of $0.32 per share for a total of 109,375 shares per the terms of the consulting agreement executed in February 2019. On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020. This warrant will have an exercise price equal to the price per share at which securities were offered to investors for purchase at the Qualified Financing, which was $0.014, and is exercisable beginning on the day immediately following the closing of the Rights Offering, which occurred on September 11, 2020. On July 28, 2020, the Company issued an aggregate of 17,893,076 shares of its common stock upon the conversion of all of its issued and outstanding Series B and Series D Preferred Stock (the “Preferred Stock”) and accumulated dividends. The Preferred Stock was converted pursuant to a mandatory conversion triggered by the majority holder of the Series D Preferred Stock as set forth in the Certificate of Designations for the Series D Preferred Stock. On July 29, 2020, the Company filed its Second Amended and Restated Certificate of Incorporation (the “Amended COI”). The Amended COI provides for the issuance of up 1,600,000,000 shares of Common Stock and 1,000,000,000 shares of Preferred Stock, of which 800,000,000 shares are designated as Series A Preferred Stock and eliminates the previously authorized classes of preferred stock. The Amended COI also delineates the rights of the Series A Preferred Stock. Series A Preferred Stock On September 11, 2020, the registered Rights Offering (Registration No. 333-239629) of the Company expired. Pursuant to the Rights Offering, on September 24, 2020, the Company issued (i) 15,235,381 shares of its Series A preferred stock at a price of $0.014 per share to holders of its common stock who validly exercised their subscription rights prior to the expiration time and (ii) 203,049,643 shares of its Series A preferred stock to the standby purchasers as part of the standby commitment. The Rights Offering, including the standby component, resulted in gross proceeds to the Company of $3,055,985. Additionally, on September 24, 2020, the Company issued an aggregate of 323,844,416 shares of its Series A Preferred Stock to the holders of outstanding promissory notes, issued in April 2020, in the aggregate principal amount and accrued interest of $4,483,617. The notes were converted pursuant to mandatory conversion triggered by the completion of the Rights Offering (for further discussion, see Note 9-”Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). During the quarter ended March 31, 2021, 9,679,834 shares of Series A Preferred Stock were converted to Common Stock at the request of certain Series A Preferred Shareholders. Voting Rights Holders of Series A Preferred Stock (“Series A Holders”) have the right to receive notice of any meeting of holders of common stock or Series A Preferred Stock and to vote upon any matter submitted to a vote of the holders of common stock or Series A Preferred Stock. Each Series A Holder shall vote on each matter on an as converted basis submitted to them with the holders of common stock. Conversion Series A Preferred Stock converts to common stock at a 1:1 ratio immediately upon request of the Series A Holder. Liquidation Series A Preferred Stock does not have preferential treatment over common stock shareholders if the Company liquidates or dissolves. Stock-Based Compensation Plan The Company utilizes the Black-Scholes valuation method to recognize stock-based compensation expense over the vesting period. The expected life represents the period that the stock-based compensation awards are expected to be outstanding. Stock Option Activity For the three months ended March 31, 2021 and 2020, all outstanding stock options were fully vested, and related compensation expense recognized. On April 1, 2021, the Board of Directors of the Company approved and granted an aggregate of 49,750,000 stock options to certain directors and officers of the Company having an exercise price of $0.07 per share and an expiration date of ten years from the date of grant. These options are not included in the Company’s current stock option plan as they were granted outside of the plan (see Note 14). The following is a summary of stock option activity for the three months ended March 31, 2021 and 2020: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled — — — Outstanding and exercisable at March 31, 2020 425,000 $ 1.38 7.46 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted — — — Expired/Cancelled — — — Outstanding and exercisable at March 31, 2021 410,000 $ 1.39 6.48 Non-Controlling Interest For the three months ended March 31, 2021 and 2020, the Company consolidated the results for LI Dallas, LI Nashville, LI Pittsburgh and LI Scottsdale as VIEs. The Company owns no portion of any of these four entities which own their respective clinics; however, the Company maintains control through their management role for each of the clinics, in accordance with each clinic’s respective management services agreement. Based on these agreements, the Company has the responsibility to run and make decisions on behalf of the clinics, except for medical care and procedures. Beginning in January 2018, the Company adopted the policy, for all of the VIEs, that the management fee charged by the Company would equal the amount of net income from each VIE on a monthly basis, bringing the amount of the net income to $0 each month for the VIEs. Due to this change in policy, there was no change in the non-controlling interest for the three months ended March 31, 2021 or 2020 related to the net income (loss) as it was $0 each month through the management fee charged by the Company. Net Loss Per Share Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are antidilutive due to the Company’s net losses. For the three month period ended March 31, 2021, the Company had 528,429,575 shares outstanding of Series A Preferred Stock which converts on a 1:1 ratio to common stock and would be considered dilutive upon conversion. In addition, 389,486,207 warrants outstanding at March 31, 2021 are potentially dilutive as their exercise price is below the current stock price. There is no difference between the basic and diluted net loss per share when including the remaining 23,937,765 warrants outstanding with an exercise price above the current stock price and 410,000 in outstanding common stock options as they are considered anti-dilutive and excluded for the period ended March 31, 2021 due to the net loss. For the three month period ended March 31, 2020, there is no difference between the basic and diluted net loss per share: 45,319,643 warrants and 425,000 common stock options outstanding were considered anti-dilutive and were excluded.

Commitments & Contingencies

Commitments & Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments & Contingencies	Note 8 – Commitments & Contingencies Litigation From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect the Company’s financial condition, results of operations, and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention, and other factors. The Company expenses legal costs in the period incurred. The Company cannot assure that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against the Company in the future, and these matters could relate to prior, current or future transactions or events. As of March 31, 2021, the Company had no litigation matters which required any accrual or disclosure. Guarantee The Company has guaranteed payments based upon the terms found in the management services agreements to affiliated physicians related to LI Dallas, LI Nashville, LI Pittsburgh, and LI Scottsdale. For the three months ended March 31, 2021 and 2020, payments totaling approximately $17,000 and $22,000, respectively, were made to these physicians’ legal entities. Due to COVID-19, the Company temporarily ceased operations effective March 23, 2020 in LI Dallas, LI Pittsburgh, LI Scottsdale, LI Nashville, and LI Tampa, at which time, the guaranteed payments for these clinics were suspended. The guaranteed payments did not resume for LI Dallas and LI Pittsburgh due to them presently being closed. The Company resumed guaranteed payments in January 2021 for LI Nashville and LI Scottsdale. Rion Agreements On June 21, 2019, H-CYTE entered into an exclusive product supply agreement with Rion, LLC (“Rion”) to develop and distribute (post FDA approval) a biologic for chronic obstructive pulmonary disease (“COPD”), the fourth leading cause of death in the U.S. Rion has established a novel biologics technology to harness the healing power of the body. Rion’s innovative technology, based on science developed at Mayo Clinic, provides an off-the-shelf platform to enhance healing in soft tissue, musculoskeletal, cardiovascular and neurological organ systems. This agreement provides for a 10-year exclusive and extendable supply agreement with Rion to enable H-CYTE to develop proprietary biologics. On October 9, 2019, the Company entered into a services agreement with Rion which provides the Company the benefit of Rion’s resources and expertise for the limited purpose of (i) consulting with and assisting H-CYTE in the further research and development for the generation of a new biologic and (ii) subsequently assisting H-CYTE in seeking and obtaining FDA Phase 1 IND clearance for this biologic as necessary. Rion also agrees to consult with H-CYTE in its arrangement for services from third parties unaffiliated with Rion to support research, development, regulatory approval, and commercialization of the biologic. An additional $350,000 in expense is expected to be incurred per the Rion Agreements. At this time, the Company is not able to estimate when this expense will occur. For the periods ending March 31, 2021 and 2020, the Company expensed $0 and $750,000, respectively, related to these agreements.

Short-Term Debt

Short-Term Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Short-Term Debt	Note 9 – Short-term Debt Convertible note The Convertible Notes payable represents a securities purchase agreement with select accredited investors, which was assumed in the Asset Purchase Agreement between Medovex, Corp and Regenerative Medicine Solutions, LLC (“Merger”) in 2019 (see Note 1 – “Description of the Company” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K) . The debt assumed by the Company consisted of $750,000 of units (the “Units”) with a purchase price of $50,000 per Unit. Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company’s common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company’s common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40. The Convertible Notes were secured by all of the assets of the Company. In 2019, $100,000 of the Convertible Notes were converted into shares of common stock, and $350,000 of the Convertible Notes were redeemed by the Company. The Company reached an extension with the remaining noteholder which extended the maturity date of the Hawes Notes for one year, until September 30, 2020. The notes had a principal balance of $300,000 plus penalties of approximately $85,000 and accrued interest of approximately $40,000 for a total adjusted principal balance upon renewal of $424,615 as of March 31, 2020. In connection with the April Offering, the Company entered into an amendment with the Investor with respect to the outstanding 12% Senior Secured Convertible Note due September 30, 2020, which was originally issued in 2018 and assumed in the Merger and which was purchased by the Investor from its original holder, George Hawes, on March 27, 2020 (see Note 11-”Debt” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). Notes Payable Notes payable were assumed in the Merger and are due in aggregate monthly installments of approximately $5,800 and carry an interest rate of 5%. Each note originally had a maturity date of August 1, 2019. The Company finalized an eighteen-month extension to March 1, 2021. The Company is working with the lender for an additional extension of the promissory notes. The promissory notes have an aggregate outstanding balance of approximately $67,000 at March 31, 2021 and December 31, 2020. The Company has not made payments on this note since February 10, 2020, due to COVID-19, resulting in accrued interest of approximately $4,000. On March 27, 2020, the Company issued a demand note in the principal amount of $500,000 to FWHC Bridge, LLC (the “Investor”) in exchange for a loan made by the Investor in such amount to cover the Company’s working capital needs. Subsequently on April 9, 2020, in exchange for an additional loan of $500,000 made by the Investor to the Company, the Company amended and restated the demand note to reflect a new principal amount of $1,000,000, which became the “A&R Note (see Note 11-”Debt” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). The short-term notes with related parties were issued by the Company during 2019, and as of March 31, 2020 consisted of four loans totaling $1,635,000, made to the Company by Horne Management, LLC, controlled by the former Chief Executive Officer, William E. Horne, for working capital purposes. The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020. Some of these loans provided for the issuance of warrants at 114% warrant coverage if the loan was not repaid within two months. None of these loans were repaid and 840,000 warrants were issued at an exercise price of $0.75 per share. On April 23, 2020, Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company’s common stock with such conversion to be effective as of April 17, 2020 (see Note 11-”Debt” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K). Paycheck Protection Program On April 29, 2020, the Company issued a promissory note in the principal amount of $809,082 to the Bank of Tampa in connection with a loan in such amount made under the Paycheck Protection Program (“PPP Loan”). The PPP Loan bears interest at a rate of 1% per annum and is payable in eighteen monthly payments of $45,533 beginning on approximately August 14, 2021. The Company elected to use a 24-week Covered Period, per the SBA Paycheck Protection Program guidelines, the Covered Period ended on October 14, 2020. The Company can apply for loan forgiveness in an amount equal to the sum of the following costs incurred by the Company: 1) payroll costs; 2) any payment of interest on covered mortgage obligations; 3) any payment on a covered rent obligation; and 4) any covered utility payment The amount forgiven will be calculated (and may be reduced) in accordance with the Paycheck Protection Program criteria set by the SBA. Not more than 40% of the amount forgiven can be attributed to non-payroll costs, as listed above. As long as a borrower submits its loan forgiveness application within ten months of the completion of the Covered Period (as defined below), the borrower is not required to make any payments until the forgiveness amount is remitted to the lender by SBA. If the loan is fully forgiven, the borrower is not responsible for any payments. If only a portion of the loan is forgiven, or if the forgiveness application is denied, any remaining balance due on the loan must be repaid by the borrower on or before the maturity date of the loan. Interest accrues during the time between the disbursement of the loan and SBA remittance of the forgiveness amount. The borrower is responsible for paying the accrued interest on any amount of the loan that is not forgiven. The lender is responsible for notifying the borrower of remittance by SBA of the loan forgiveness amount (or that SBA determined that no amount of the loan is eligible for forgiveness) and the date on which the borrower’s first payment is due, if applicable. The Company filed its forgiveness application on April 20, 2021.

Derivative Liability - Warrants

Derivative Liability - Warrants	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability - Warrants	Note 10 – Derivative Liability - Warrants The Company’s derivative liabilities are classified within Level 3 of the fair value hierarchy because certain unobservable inputs were used in the valuation models. These assumptions included estimated future stock prices, potential down-round financings for the Warrants, and potential redemptions for the Redemption Put Liability. The following are rollforwards of the liabilities measured at fair value during the three months ended March 31, 2020: Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Fair value adjustments (174,978 ) Balance at March 31, 2020 $ 140,877 Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,305 Fair value adjustments (193,659 ) Balance at March 31, 2020 $ 79,045 The Company did not have any assets or liabilities measured at fair value using Level 1 or 2 of the fair value hierarchy as of December 31, 2020 (see Note 12-”Derivative Liability-Warrants and Redemption Put” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Common Stock Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Common Stock Warrants	Note 11 - Common Stock Warrants A summary of the Company’s warrant issuance activity and related information for the quarters ended March 31, 2021 and 2020: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 513,567 0.75 6.13 Outstanding and exercisable at March 31, 2020 45,319,643 $ 0.78 4.61 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Issued — — — Total outstanding at March 31, 2021 413,423,972 0.10 9.24 The fair value of all warrants issued are determined by using the Black-Scholes valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued. The inputs used in the Black-Scholes valuation technique to value each of the warrants as of their respective issue dates are as follows: Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97 The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Series D Convertible Preferred

Series D Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Series D Convertible Preferred Stock	Note 12 - Series D Convertible Preferred Stock On November 15, 2019, the Company entered into a securities purchase agreement with selected accredited investors whereby the Company offered (i) up to 238,871 shares of Series D Convertible Preferred Stock the (“Series D Shares”) at a price of $40.817 per share and (ii) a ten-year warrant (the “Series D Warrant”) to purchase 14,669,757 shares of common stock. The Series D Warrants are exercisable for a period of 10 years from issuance at an initial exercise price of $0.75 per share, subject to adjustment for traditional equity restructurings and reorganizations. On November 21, 2019, the Company entered into a securities purchase agreement with FWHC Holdings, LLC (“FWHC”) an accredited investor for the purchase of 146,998 shares of Series D Preferred Stock, par value $0.001 per share and the Series D Warrant (the “FWHC Investment”). See Note 14-”Mezzanine Equity and Series D Convertible Preferred Stock” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K. For the three months ended March 31, 2021 and 2020, the Company recorded $0 and $158,147 in deemed dividends on the Series D Convertible Preferred Stock in accordance with the 8% stated dividend resulting in a total balance of Series D Convertible Preferred stock of $6,281,433 at March 31, 2020. All outstanding shares of Series D Convertible Preferred Stock were converted into 15,773,363 shares of Common Stock on July 28, 2020. The conversion was pursuant to a mandatory conversion triggered by the majority holder of the Series D Convertible Preferred Stock as set forth in the Certificate of Designations. As of December 31, 2020, the Company does not have any Series D Convertible Preferred Stock outstanding (see Note 9-”Equity Transactions” to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K).

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Taxes
Income Taxes	NOTE 13 – Income Taxes The Company utilizes the liability method of accounting for income taxes as set forth in FASB ASC Topic 740, “Income Taxes”. Under the liability method, deferred taxes are determined based on temporary differences between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect during the years in which the difference turns around. The Company accounts for interest and penalties on income taxes as income tax expense. A valuation allowance is recorded when it is more likely than not that a tax benefit will not be realized. In determining the need for valuation allowances the Company considers projected future taxable income and the availability of tax planning strategies. From inception to March 31, 2021, the Company has incurred net losses and, therefore, has no current income tax liability. The net deferred tax asset generated by these losses is fully offset by a valuation allowance as of March 31, 2021 and December 31, 2020. Management of the Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets. The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. There are no uncertain tax positions at March 31, 2021 and December 31, 2020. The Company has not undergone any tax examinations since inception.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	N ote 14 - Subsequent Events On April 1, 2021, the Company entered into a Secured Convertible Note Purchase Agreement (the “April 2021 Note Purchase Agreement”) with five (5) investors (the “Holders”). Pursuant to the terms of the April 2021 Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $2,575,000. The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8%. The Notes are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the April 2021 Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the April 2021 Note Purchase Agreement, FWHC Bridge, LLC, advanced $1,500,000 of the total amount to the Company. FWHC is an affiliated entity of FWHC, LLC which is a principal stockholder of the Company. An additional affiliate of FWHC LLC advanced an additional $25,000 (for further information, including the Note Purchase Agreement exhibits, refer to the Company’s Form 8-K filed on April 7, 2021). Since the number of shares the holder will receive upon a Qualified Financing is not known until the financing occurs, a contingent beneficial conversion feature will be calculated and recorded when the financing is completed. On April 1, 2021, the Board of Directors of the Company approved and granted an aggregate of 49,750,000 stock options to certain directors and officers of the Company having an exercise price of $0.07 per share and an expiration date of ten years from the date of grant. The Director’s options vest over a period of three years, and the Chief Executive Officer’s and Chief Financial Officer’s options vest over a period of four years. A certain number of the options were vested immediately. The options were priced based on the closing price of the Company’s common stock on the date prior to the grant. These options are not included in the Company’s current stock option plan as they were granted outside of the plan. On April 2, 2021, the Company entered into a series of agreements (ollectively the “Agreements”) with Medovex LLC, a limited liability company formed on December 8, 2020, to pursue a joint venture regarding the continued development and commercialization of the DenerveX Device for business outside of the U.S. Pursuant to the terms of the Agreements, the Company assigned and contributed personal property and related rights, consisting of all the tangible assets relating to the DenerveX rotational ablation denervation device (the “DenerveX Device”) in exchange for (i) a secured convertible promissory note in the original principal amount of $140,000 (the “DenerveX Note”) and (ii) 400,000 Class B Units of Medovex LLC (the “Exchange Units”). The 400,000 Class B Units represent approximately 22% of the currently outstanding membership interests of Medovex LLC. In addition, pursuant to the Intellectual Property Agreement, the Company will receive a royalty of 6% of gross revenues derived from the sale or licensing of the DenerveX Device (no royalty will be payable upon the first $666,667 of gross revenues) during the life of the underlying patent and 2% thereafter. The Company did not give up any of the intellectual property ownership related to the DenerveX Device. Medovex LLC also assumed all of the Company’s existing and future obligations related to the DenerveX Device (for further information, including the Agreements exhibits, refer to the Company’s Form 8-K filed on April 8, 2021). As of May 12, 2021, an additional 7,594,932 Series A Preferred Stock was converted into Common Stock at the request of certain Series A Preferred Stockholders.

Right-of-use Asset and Lease _2

Right-of-use Asset and Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Components of Lease Expense	The components of lease expense, which are included in other general and administrative expense, for the three months ended March 31, 2021 and 2020, respectively, are as follows: Three months Ended March 31, 2021 2020 Operating lease expense $ 108,593 $ 150,564
Schedule of Cash Paid for Amounts Included the Measurement of Lease Liabilities	Cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2021 and 2020, respectively, are as follows: Three months Ended March 31, 2021 2020 Operating cash flows from operating leases $ 108,593 $ 150,564
Schedule of Supplemental Balance Sheet and Other Information	Supplemental balance sheet and other information related to operating leases are as follows: March 31, 2021 December 31, 2020 Operating leases right-of-use assets $ 204,546 $ 278,552 Lease liability, current portion 87,939 139,189 Lease liability, net of current portion 134,295 157,050 Total operating lease liabilities $ 222,234 $ 296,239 Weighted average remaining lease term 2.42 years 2.32 years Weighted average discount rate 11.57 % 10.31 %
Schedule of Maturities of Lease Liabilities	Future maturities of operating lease liabilities as of March 31, 2021 are as follows: Operating leases Remainder of 2021 $ 75,712 2022 102,891 2023 69,333 Total lease payments 247,936 Less: Interest (25,702 ) Total lease liability $ 222,234

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net, consists of the following: Useful Life March 31, 2021 December 31, 2020 Furniture and fixtures 5-7 years $ 231,222 $ 231,222 Computers and software 3-7 years 247,844 246,323 Leasehold improvements 15 years 155,583 155,583 634,649 633,128 Less: accumulated depreciation (505,523 ) (493,953 ) Total $ 129,126 $ 139,175

Equity Transactions (Tables)

Equity Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity for the three months ended March 31, 2021 and 2020: Shares Weighted Average Exercise Price Weighted Average Remaining Term (Years) Outstanding at December 31, 2019 425,000 $ 1.38 7.71 Granted — — — Expired/Cancelled — — — Outstanding and exercisable at March 31, 2020 425,000 $ 1.38 7.46 Outstanding at December 31, 2020 410,000 $ 1.39 6.72 Granted — — — Expired/Cancelled — — — Outstanding and exercisable at March 31, 2021 410,000 $ 1.39 6.48

Derivative Liability - Warran_2

Derivative Liability - Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value, Liabilities Measured on Recurring Basis	The following are rollforwards of the liabilities measured at fair value during the three months ended March 31, 2020: Derivative Liability - Warrants Balance at December 31, 2019 $ 315,855 Fair value adjustments (174,978 ) Balance at March 31, 2020 $ 140,877 Redemption Put Liability Balance at December 31, 2019 $ 267,399 Issuance of Series D Convertible Preferred Stock 5,305 Fair value adjustments (193,659 ) Balance at March 31, 2020 $ 79,045

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Warrant Activity	A summary of the Company’s warrant issuance activity and related information for the quarters ended March 31, 2021 and 2020: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Outstanding and exercisable at December 31, 2019 44,806,076 $ 0.78 4.59 Issued 513,567 0.75 6.13 Outstanding and exercisable at March 31, 2020 45,319,643 $ 0.78 4.61 Outstanding and exercisable at December 31, 2020 413,423,972 $ 0.015 10.30 Issued — — — Total outstanding at March 31, 2021 413,423,972 0.10 9.24
Schedule of Assumptions for Warrants	The inputs used in the Black-Scholes valuation technique to value each of the warrants as of their respective issue dates are as follows: Event Description Date Number of Warrants H-CYTE Stock Price Exercise Price of Warrant Grant Date Fair Value Life of Warrant Risk Free Rate of Return (%) Annualized Volatility Rate (%) Short-term note, related party 1/13/2020 268,571 $ 0.12 $ 0.75 $ 0.07 3 years 1.60 145.76 Private placement of Series D Convertible Preferred Stock 1/17/2020 244,996 $ 0.15 $ 0.75 $ 0.13 10 years 1.84 144.30 Granted for bridge financing 4/8/2020 296,875 $ 0.05 $ 0.40 $ 0.04 3 years 0.34 131.82 Short-term note, related party conversion 4/17/2020 4,368,278 $ 0.05 $ 0.014 $ 0.05 10 years 0.65 100.64 Granted for bridge financing 9/11/2020 364,439,176 $ 0.05 $ 0.014 $ 0.017 10 years 0.65 96.97

Description of the Company (Det

Description of the Company (Details Narrative)	3 Months Ended
	Mar. 31, 2021	Sep. 11, 2020
FWHC, LLC [Member]
Equity ownership percentage		61.00%
Rion LLC [Member] | Product Supply Agreement [Member]
Agreement term	10 years

Liquidity, Going Concern and _2

Liquidity, Going Concern and Management's Plans (Details Narrative) - USD ($)	Apr. 01, 2021	Apr. 23, 2020	Apr. 17, 2020	Apr. 09, 2020	Mar. 31, 2021	Mar. 31, 2020	May 13, 2021	Dec. 31, 2020	May 13, 2020	Mar. 27, 2020	Mar. 26, 2020
Net loss					$ (1,407,674)	$ (2,416,228)
Cash on hand					332,310			$ 1,640,645
Subsequent Event [Member]
Cash on hand							$ 2,133,000
Investor [Member]
Debt principal amount				$ 500,000
Series B Preferred Stock [Member]
Net loss
William E. Horne [Member] | Horne Management, LLC [Member]
Debt interest rate									12.00%		5.50%
Warrants exercise price, per share					$ 0.75
Debt conversion of common stock shares		4,368,278
Short-term notes						1,635,000
Debt interest rate description					The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020.
Coverage rate description					Some of these loans provided for the issuance of warrants at 114% warrant coverage if the loan was not repaid within two months.
Qualified financing, per share					$ 0.014
Number of warrants issued					840,000
Debt conversion description		Horne Management, LLC agreed to convert the related notes plus accrued interest into (i) 4,368,278 shares of common stock of the Company and (ii) a ten-year warrant to purchase up to an equivalent number of shares of the Company's common stock with such conversion to be effective as of April 17, 2020. This warrant has an exercise price equal to the price per share at which securities were offered to investors for purchase at the Qualified Financing totaling $0.014 and is exercisable beginning on the day immediately following the earlier to occur of (x) the closing of the Qualified Financing and (y) November 1, 2020. The Qualified Financing closed on September 11, 2020.
April Secured Notes [Member]
Trigger price per share			$ 0.014
April Secured Notes [Member] | Series A Preferred Stock [Member]
Debt conversion of common stock shares			287,984,337
April Secured Notes [Member] | Series B Preferred Stock [Member]
Warrants exercise price, per share			$ 0.014
Hawes Note [Member]
Debt principal amount						$ 424,615
Hawes Note [Member] | Series A Preferred Stock [Member]
Debt conversion of common stock shares			35,860,079
Note [Member] | Investor [Member]
Debt principal amount										$ 500,000
Total amount in exchange for loans				1,000,000
A&R Note [Member] | Investor [Member]
Debt principal amount				$ 1,000,000
Debt interest rate				12.00%
Secured Convertible Note and Warrant Purchase Agreement [Member]
Proceeds from secured convertible promissory notes			$ 2,842,695
Secured Convertible Note and Warrant Purchase Agreement [Member] | April Secured Notes [Member]
Debt principal amount			$ 3,842,695
Debt interest rate			12.00%
Secured Convertible Note and Warrant Purchase Agreement [Member] | April Secured Notes [Member] | Investor [Member]
Debt principal amount			$ 1,000,000
Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member]
Debt principal amount	$ 2,575,000
Debt interest rate	8.00%
Debt instrument maturity date	Mar. 31, 2022
Debt instrument conversion discount price percentage	20.00%
Secured Convertible Note Purchase Agreement [Member] | Investor [Member] | FWHC Bridge, LLC [Member] | Subsequent Event [Member]
Proceeds from convertible debt	$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | Investor [Member] | FWHC [Member] | Subsequent Event [Member]
Proceeds from convertible debt	$ 25,000

Right-of-use Asset and Lease _3

Right-of-use Asset and Lease Liability (Details Narrative) - Tampa, FL [Member] - Subsequent Event [Member]	Apr. 01, 2021USD ($)
Lease, description	The Company did not renew its corporate office space lease in Tampa, FL which expired on March 31, 2021. The Company leases medical clinic space in Tampa, FL, Nashville, TN, and Scottsdale, AZ. These clinic locations have various expiration dates through August 31, 2023. The leasing arrangements contain various renewal options that are adjusted for increases in the consumer price index or agreed upon rates. The Company entered into a short-term lease for its Tampa location beginning April 1, 2021 totaling $71,775. The Dallas, TX lease expired on July 31, 2020 and the Pittsburgh, PA lease expired on October 31, 2020, neither of which were renewed as these clinic locations were permanently closed.
Short-term lease commitment, amount	$ 71,775

Right-of-use Asset and Lease _4

Right-of-use Asset and Lease Liability - Schedule of Components of Lease Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating lease expense	$ 108,593	$ 150,564

Right-of-use Asset and Lease _5

Right-of-use Asset and Lease Liability - Schedule of Cash Paid for Amounts Included the Measurement of Lease Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 108,593	$ 150,564

Right-of-use Asset and Lease _6

Right-of-use Asset and Lease Liability - Schedule of Supplemental Balance Sheet and Other Information (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating leases right-of-use assets	$ 204,546	$ 278,552
Lease liability, current	87,939	139,189
Lease liability, net of current portion	134,295	157,050
Total operating lease liabilities	$ 222,234	$ 296,239
Weighted average remaining lease term	2 years 5 months 1 day	2 years 3 months 26 days
Weighted average discount rate	11.57%	10.31%

Right-of-use Asset and Lease _7

Right-of-use Asset and Lease Liability - Schedule of Maturities of Lease Liabilities (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating leases: Remainder of 2021	$ 75,712
Operating leases: 2022	102,891
Operating leases: 2023	69,333
Operating leases: Total lease payments	247,936
Less: Interest	(25,702)
Total lease liability	$ 222,234	$ 296,239

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 12,000	$ 22,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property and equipment	$ 634,649	$ 633,128
Less: accumulated depreciation	(505,523)	(493,953)
Property and Equipment, net	129,126	139,175
Furniture and Fixtures [Member]
Property and equipment	$ 231,222	231,222
Furniture and Fixtures [Member] | Minimum [Member]
Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Useful Life	7 years
Computers and Software [Member]
Property and equipment	$ 247,844	246,323
Computers and Software [Member] | Minimum [Member]
Useful Life	3 years
Computers and Software [Member] | Maximum [Member]
Useful Life	7 years
Leasehold Improvements [Member]
Useful Life	15 years
Property and equipment	$ 155,583	$ 155,583

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 12, 2021	Oct. 02, 2020	Sep. 11, 2020	Jul. 28, 2020	Mar. 25, 2020	Feb. 01, 2019	Mar. 31, 2021	Mar. 31, 2020
Series A Preferred Stock [Member]
Conversion of stock, shares issued			117,362,143
Series A Preferred Stock [Member] | Promissory Notes from April 2020 [Member]
Conversion of stock, shares issued			123,031,819
Series A Preferred Stock [Member] | April Secured Note [Member]
Conversion of stock, shares issued			75,162,429
Series A Preferred Stock [Member] | Hawes Notes [Member ]
Conversion of stock, shares issued			35,860,079
FWHC HOLDINGS, LLC [Member]
Percentage of fully diluted shares owned			61.00%
Warrants issued			273,356,676
Warrants term			10 years
Warrants exercise price, per share			$ 0.014
FWHC HOLDINGS, LLC [Member] | Series D Convertible Preferred Stock [Member]
Conversion of stock, shares issued				15,518,111
Mr. Raymond Monteleone [Member]
Officers compensation							$ 17,500	$ 30,000
Oral Consulting Agreement [Member]
Advisory service fee					$ 5,000
Audit fees					$ 2,500
Oral Consulting Agreement [Member] | Mr. Raymond Monteleone [Member]
Advisory service fee						$ 10,000
Audit fees	$ 5,000					$ 5,000
Receive compensation per month	4,167
Oral Consulting Agreement [Member] | Michael Yurkowsky [Member]
Audit fees		$ 4,167
Officers compensation							12,500	0
Oral Consulting Agreement [Member] | Mr. William Horne [Member]
Audit fees	$ 4,167
Officers compensation							$ 4,000	$ 0

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	Apr. 01, 2021	Sep. 24, 2020	Jul. 29, 2020	Jul. 28, 2020	Apr. 23, 2020	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2020
Authorized shares, description			The Company filed its Second Amended and Restated Certificate of Incorporation (the "Amended COI"). The Amended COI provides for the issuance of up 1,600,000,000 shares of Common Stock and 1,000,000,000 shares of Preferred Stock, of which 800,000,000 shares are designated as Series A Preferred Stock and eliminates the previously authorized classes of preferred stock. The Amended COI also delineates the rights of the Series A Preferred Stock.
Stock options granted during period
Stock options granted, exercise price per share
Management fee							$ 0	$ 0
Directors and Officers [Member] | Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member]
Stock options granted during period	49,750,000
Stock options granted, exercise price per share	$ 0.07
Stock options expiration period	10 years
Series A Preferred Stock [Member]
Share issued price per share		$ 0.014
Stock issued during period new issue shares		15,235,381
Number of shares converted							9,679,834
Potentially anti-dilutive, share							528,429,575
Series A Preferred Stock [Member] | Promissory Note [Member]
Stock issued during period new issue shares		323,844,416
Series A Preferred Stock [Member] | Outstanding Promissory Notes [Member]
Stock issued during period new issue shares		323,844,416
Principal amount and accrued interest		$ 4,483,617
Series A Preferred Stock [Member] | Purchasers [Member]
Stock issued during period new issue shares		203,049,643
Proceeds from offering		$ 3,055,985
Series B and Series D Preferred Stock [Member]
Debt conversion of common stock shares				17,893,076
Warrants [Member]
Potentially anti-dilutive, share							389,486,207	45,319,643
Warrant outstanding							23,937,765
Common Stock [Member]
Potentially anti-dilutive, share							410,000	425,000
LilyCon Investments, LLC [Member]
Value of shares issued for services						$ 35,000
Share issued price per share						$ 0.32
Number of shares issued for services						109,375
Home Management LLC [Member]
Debt conversion of common stock shares					4,368,278
Debt conversion price per share					$ 0.014

Equity Transactions - Summary o

Equity Transactions - Summary of Stock Option Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Number of Shares Options Outstanding Beginning Balance	410,000	425,000
Number of Options Granted
Number of Options Expired/Cancelled
Number of Shares Options Outstanding and exercisable Ending Balance	410,000	425,000
Weighted Average Exercise Price Outstanding Beginning Balance	$ 1.39	$ 1.38
Weighted Average Exercise Price Granted
Weighted Average Exercise Price Expired/ Cancelled
Weighted Average Exercise Price Outstanding and exercisable Ending Balance	$ 1.39	$ 1.38
Weighted Average Remaining Term (years) Outstanding, Beginning	6 years 8 months 19 days	7 years 8 months 16 days
Weighted Average Remaining Term (years) Assumed with the RMS merger transaction	0 years	0 years
Weighted Average Remaining Term (years) Granted	0 years	0 years
Weighted Average Remaining Term (years) Outstanding and exercisable Ending	6 years 5 months 23 days	7 years 5 months 16 days

Commitments & Contingencies (De

Commitments & Contingencies (Details Narrative) - USD ($)	Oct. 09, 2019	Mar. 31, 2021	Mar. 31, 2020
Guarantor obligations		$ 17,000	$ 22,000
Research and development expense			750,000
Rion Agreement [Member] | Rion LLC [Member]
Expenses incurred upon achievement of milestones	$ 350,000
Research and development expense		$ 0	$ 750,000

Short-Term Debt (Details Narrat

Short-Term Debt (Details Narrative) - USD ($)	Apr. 29, 2020	Apr. 23, 2020	Mar. 31, 2021	Dec. 31, 2019	Dec. 31, 2020	Apr. 09, 2020	Mar. 27, 2020
Common stock, par value			$ 0.001		$ 0.001
Warrants [Member]
Number of warrants issued			840,000
Warrants exercise price, per share			$ 0.016
Home Management LLC [Member]
Market value of common stock		$ 0.014
Warrant term		10 years
Number of shares issued on conversion		4,368,278
Consisting of Five Loans [Member] | Home Management LLC [Member]
Notes payable			$ 1,635,000
Consisting of Five Loans [Member] | Home Management LLC [Member] | Minimum [Member]
Debt instrument interest rate			5.50%
Debt, maturity date			Mar. 26, 2020
Consisting of Five Loans [Member] | Home Management LLC [Member] | Maximum [Member]
Debt instrument interest rate			12.00%
Consisting of Four Loans [Member] | Home Management LLC [Member] | Maximum [Member]
Debt, maturity date			May 13, 2020
Investor [Member]
Notes payable						$ 500,000	$ 500,000
William E. Horne [Member] | Home Management LLC [Member]
Debt interest rate description			The loans bore interest rates ranging from 5.5% to 12%, in some cases increasing to 15% if not paid by the respective maturity date ranging from March 26, 2020 to May 13, 2020.
Third Noteholder [Member]
Notes payable			$ 300,000
Fees and penalties			85,000
Accrued interest			40,000
Debt principal amount			$ 424,615
Notes Payable [Member] | Merger [Member]
Debt description			The Company finalized an eighteen-month extension to March 1, 2021.
Accrued interest			$ 4,000
Monthly installment amount			$ 5,800
Debt instrument interest rate			5.00%
Debt, maturity date			Aug. 1, 2019
Promissory Notes [Member]
Notes payable			$ 67,000	$ 67,000
New Principal Amount [Member] | Investor [Member]
Notes payable						$ 1,000,000
Securities Purchase Agreement [Member] | Accredited Investors [Member]
Number of common stock shares sold, value			$ 750,000
Sale of stock price per share			$ 50,000
Debt description			Each Unit consists of (i) a 12% senior secured convertible note, initially convertible into shares of the Company's common stock, par value $0.001 per share, at a conversion price equal to the lesser of $0.40 or ninety percent (90%) of the per share purchase price of any shares of common stock or common stock equivalents issued in future private placements of equity and/or debt securities completed by the Company following this offering, and (ii) a three-year warrant to purchase such number of shares of the Company's common stock equal to one hundred percent (100%) of the number of shares of common stock issuable upon conversion of the notes at $0.40.
Conversion of common stock, percentage			12.00%
Common stock, par value			$ 0.001
Market value of common stock			$ 0.40
Warrant term			3 years
Debt converted into shares, value				100,000
Redeemed convertible notes value				$ 350,000
Payroll Protection Program [Member]
Debt principal amount	$ 809,082
Debt instrument interest rate	1.00%
Debt repayments, description	The PPP Loan bears interest at a rate of 1% per annum and is payable in eighteen monthly payments of $45,533 beginning on approximately August 14, 2021. The Company elected to use a 24-week Covered Period, per the SBA Paycheck Protection Program guidelines, the Covered Period ended on October 14, 2020.
Amount forgiven to non-payroll costs, percentage	40.00%

Derivative Liability - Warran_3

Derivative Liability - Warrants - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Derivative Liability - Warrants [Member]
Beginning balance, Derivative Liability- Warrants	$ 315,855
Fair value adjustments	(174,978)
Ending balance, Derivative Liability- Warrants	140,877
Redemption Put Liability [Member]
Beginning balance, Redemption Put Liability	267,399
Issuance of Series D Convertible Preferred Stock	5,305
Fair value adjustments	(193,659)
Ending balance	$ 79,045

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Warrant Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [Abstract]
Number of Shares, Warrants Outstanding Beginning	413,423,972	44,806,076
Number of Shares, Warrants Issued		513,567
Number of Shares, Warrants Outstanding and Exercisable Ending	413,423,972	45,319,643
Weighted Average Exercise Price Outstanding	$ 0.015	$ 0.78
Weighted Average Exercise Price Warrants Issued		0.75
Weighted Average Exercise Price Outstanding and Exercisable Ending	$ 0.10	$ 0.78
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning	10 years 3 months 19 days	4 years 7 months 2 days
Weighted Average Remaining Contractual Life Warrants Outstanding, Issued	0 years	6 years 1 month 16 days
Weighted Average Remaining Contractual Life Warrants Outstanding and Exercisable	9 years 2 months 27 days	4 years 7 months 10 days

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Assumptions for Warrants (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Number of Warrants | shares	244,996
H-CYTE Stock Price	$ 0.15
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.13
Life of Warrant	10 years
Granted for Bridge Financing 04/08/2020 [Member]
Number of Warrants | shares	296,875
H-CYTE Stock Price	$ 0.05
Exercise Price of Warrant	0.40
Warrant Grant Date Fair Value	$ 0.04
Life of Warrant	3 years
Short Term Note, Related Party Conversion 04/17/2020 [Member]
Number of Warrants | shares	4,368,278
H-CYTE Stock Price	$ 0.05
Exercise Price of Warrant	0.014
Warrant Grant Date Fair Value	$ 0.05
Life of Warrant	10 years
Granted for Bridge Financing 9/11/2020 [Member]
Number of Warrants | shares	364,439,176
H-CYTE Stock Price	$ 0.05
Exercise Price of Warrant	0.014
Warrant Grant Date Fair Value	$ 0.017
Life of Warrant	10 years
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Warrant Input, Percentage	0.34
Measurement Input, Risk Free Interest Rate [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Warrant Input, Percentage	0.65
Measurement Input, Risk Free Interest Rate [Member] | Granted for Bridge Financing 9/11/2020 [Member]
Warrant Input, Percentage	0.65
Measurement Input, Stock Price Volatility [Member] | Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Warrant Input, Percentage	144.30
Measurement Input, Stock Price Volatility [Member] | Granted for Bridge Financing 04/08/2020 [Member]
Warrant Input, Percentage	131.82
Measurement Input, Stock Price Volatility [Member] | Short Term Note, Related Party Conversion 04/17/2020 [Member]
Warrant Input, Percentage	100.64
Measurement Input, Stock Price Volatility [Member] | Granted for Bridge Financing 9/11/2020 [Member]
Warrant Input, Percentage	96.97
Measurement Input, Expected Dividend Rate [Member] | Private Placement of Series D Convertible Preferred Stock 1/17/2020 [Member]
Warrant Input, Percentage	1.84
Short-term Note Related Party 1/13/2020 [Member]
Number of Warrants | shares	268,571
H-CYTE Stock Price	$ 0.12
Exercise Price of Warrant	0.75
Warrant Grant Date Fair Value	$ 0.07
Life of Warrant	3 years
Short-term Note Related Party 1/13/2020 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrant Input, Percentage	1.60
Short-term Note Related Party 1/13/2020 [Member] | Measurement Input, Stock Price Volatility [Member]
Warrant Input, Percentage	145.76

Series D Convertible Preferre_2

Series D Convertible Preferred Stock (Details Narrative) - USD ($)	Jul. 28, 2020	Nov. 21, 2019	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Sep. 11, 2020
Preferred stock, par value				$ 0.001		$ 0.001
Series D Convertible Preferred Stock [Member]
Deemed dividends				$ 0	$ 158,147
Cumulative dividends, percentage				8.00%	8.00%
Shares issued during period, value				$ 6,281,433	$ 6,281,433
Debt conversion of common stock shares	15,773,363
FWHC HOLDINGS, LLC [Member]
Warrant term							10 years
Warrants exercise price, per share							$ 0.014
Securities Purchase Agreement [Member] | FWHC HOLDINGS, LLC [Member]
Stock issued during period new issue shares		146,998
Preferred stock, par value		$ 0.001
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Share issued price per share			$ 40.817
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Maximum [Member] | Series D Convertible Preferred Stock [Member]
Stock issued during period new issue shares			238,871
Securities Purchase Agreement [Member] | Accredited Investors [Member] | Series D Convertible Preferred Stock [Member]
Warrant term			10 years
Number of warrants to purchase common stock			14,669,757
Warrants exercise price, per share			$ 0.75

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 12, 2021	Apr. 03, 2021	Apr. 02, 2021	Apr. 01, 2021	Mar. 31, 2021	Mar. 31, 2020
Stock options granted during period
Stock options granted, exercise price per share
Subsequent Event [Member] | Series A Preferred Stock [Member]
Number of stock issued during converted into common stock	7,594,932
Subsequent Event [Member] | Medovex LLC [Member] | Secured Convertible Promissory Note [Member]
Debt principal amount			$ 140,000
Subsequent Event [Member] | Medovex LLC [Member] | Secured Convertible Promissory Note [Member] | Class B Units [Member]
Shares issued on debt instrument conversion			400,000
Outstanding membership interest percentage			22.00%
Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member]
Debt principal amount				$ 2,575,000
Debt instrument maturity date				Mar. 31, 2022
Debt interest rate				8.00%
Debt instrument conversion discount price percentage				20.00%
Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member] | Directors and Officers [Member]
Stock options granted during period				49,750,000
Stock options granted, exercise price per share				$ 0.07
Stock options expiration period				10 years
Stock options vesting period				3 years
Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member] | FWHC Bridge, LLC [Member] | Investor [Member]
Proceeds from convertible debt				$ 1,500,000
Secured Convertible Note Purchase Agreement [Member] | Subsequent Event [Member] | FWHC [Member] | Investor [Member]
Proceeds from convertible debt				$ 25,000
Intellectual Property Agreements [Member] | Subsequent Event [Member] | Medovex LLC [Member]
Royalty percentage of gross revenues		2.00%	6.00%
Gross revenues			$ 666,667